Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege (Q35045303)

6 August 2017

Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege (English)

1 reference

6 August 2017

1 reference

Wei Zhang

1

1 reference

6 August 2017

Er-Xun Ding

2

1 reference

6 August 2017

Qiang Wang

3

1 reference

6 August 2017

Da-Qiao Zhu

4

1 reference

6 August 2017

Jin He

5

1 reference

6 August 2017

Yu-Li Li

6

1 reference

6 August 2017

Yuan-He Wang

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

World Journal of Gastroenterology

6 August 2017

1 reference

6 August 2017

11

1 reference

6 August 2017

23

1 reference

6 August 2017

3632-3635

1 reference

Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

The Fas counterattack: cancer as a site of immune privilege

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Regulation of the proinflammatory effects of Fas ligand (CD95L).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Inhibition of the alloantibody response by CD95 ligand

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

The Fas counterattack: a molecular mechanism of tumor immune privilege

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Human lung carcinomas express Fas ligand.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.3748%2FWJG.V11.I23.3632

Increased expression of FLIP, an inhibitor of Fas‐mediated apoptosis, in stomach cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.3748%2FWJG.V11.I23.3632

Epithelial ovarian cancer cells secrete functional Fas ligand

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315977

A role for CD95 ligand in preventing graft rejection

25 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.3748%2FWJG.V11.I23.3632

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

21 January 2018

1 reference

12 December 2020

Prognostic relevance of altered Fas (CD95)-system in human breast cancer

1 reference

12 December 2020

[The role of Fas/Fas ligand in tumorgenesis, immune escape, and counterattack in colonic cancer]

1 reference

12 December 2020

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

12 December 2020

Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer

1 reference

12 December 2020

Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma

1 reference

12 December 2020

Fas ligand on tumor cells mediates inactivation of neutrophils

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V11.I23.3632

1 reference

6 August 2017

1 reference

6 August 2017

1 reference